| Roy B. Jones, M.D.,Ph.D. |
Present Title & Affiliation
Primary Appointment
Bio Statement
Dr. Roy Jones is Professor of Medicine in the Department of Blood and Marrow Transplantation, MD Anderson Cancer Center. He received undergraduate and M.D. degrees from Duke University and a Ph.D. in medicinal chemistry from Emory University. Prior to coming to MD Anderson in 2002, he was director of informatics for the University of Colorado Cancer Center, Professor of Medicine, University of Colorado Health Sciences Center, and director of the Bone Marrow Transplant Program. Dr. Jones has served as a reviewer on several NCI Study Sections including Subcommittee D (Clinical Program Project Grants) and CONC (Clinical Oncology Study Section).
Dr. Jones is board certified in Internal Medicine and Medical Oncology. His clinical research interests are the pharmacology of high-dose chemotherapy,the developmental therapeutics of hematopoietic stem cell transplantation, and computerized approaches to the design, approval, and management of clinical trials. He is the author of more than 150 book chapters and original articles in the areas of pharmacology of intensive chemotherapy and hematopoietic stem cell transplantation (HSCT). His clinical interests include the treatment of a variety of cancers with HSCT.
Research Interests
Novel Alkylating-agent based high-dose chemotherapy regimens; informatics strategies to support BMT translational research
Office Address
Dept of Stem Cell Transplantation & Cellular Therapy
1515 Holcombe Bvld
Unit Number: Unit 423
Houston, TX 77030
Room Number: FC5.3036
Email: rbjones@mdanderson.org
Education & Training
Degree-Granting Education | |
| 1975 | Duke University Medical Center, Durham, NC, MD |
| 1972 | Emory University, Atlanta, GA, MS |
| 1972 | Emory University, Atlanta, GA, PHD |
| 1967 | Duke University, Durham, NC, BS |
Postgraduate Training | |
| 1/1980-12/1981 | Resident, Internal Medicine, Gerogetown University Medical Center, Washington, DC |
| 1/1979-1/1980 | Resident, Georgetown University Medical Center, Washington, DC |
| 1/1979-1/1980 | Investigator, Clinical Pharmacology Branch, National Cancer Institute, Bethesda, MD |
| 1/1977-1/1978 | Clinical Associate, National Cancer Institute, Bethesda, MD |
| 1/1976-1/1977 | Intern in Medicine, Duke University Medical Center, Durham, NC |
| 1/1975-12/1975 | Hematology Fellow, Duke University Medical Center, Durham, NC |
Board Certifications
| 1/1981 | American Board of Medical Oncology |
| 1/1980 | American Board of Internal Medicine |
Honors and Awards
| 2001-present | Voted, Best Doctors in America |
Selected Publications
Peer-Reviewed Original Research Articles | ||
| 1. | Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 14(6):672-84, 6/2008. PMID: 18489993. | |
| 2. | Jones RB, Vredenburgh JJ, Coniglio D, Broadwater G,. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol Blood Marrow Transplant 12(2):195-203, 2/2006. PMID: 16443517. | |
| 3. | Nieto Y, Nawaz S, Shpall EJ, Bearman SI, Murphy J, Jones RB. Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy. Clin Cancer Res 10(8):2609-17, 4/2004. PMID: 15102662. | |
| 4. | Jones RB. Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents. Cancer Treat Res 112:305-22, 2002. PMID: 12481722. | |
Book Chapters | ||
| 1. | Jones RB, Shpall EJ,Champlin, R. Hematopoietic Cell Transplantation. In: Bone Marrow Transplantation, 879-897, 2006. | |
| 2. | Tew Kenneth D., Colvin O.M, Jones Roy B. Clinical and High-Dose Alkylating Agents. In: Cancer Chemotherapy & Biotherapy; Principles and Practice,, fourth edition, 283-309, 2005. | |
Last updated: 8/28/2009
- Global Navigation
- About Us
- Locations
- Events
- Careers
- Publications
- How You Can Help
- Contact Us
- Newsroom
- Site Index
- Patient & Cancer Information
- myMDAnderson
- Cancer Information
- Patient Information
- Care Centers & Clinics
- Children’s Cancer Hospital
- Services & Amenities
- Physician Directory
- Education and Research
- Departments, Programs & Labs
- PeopleFinder
- Research at M.D Anderson
- Education & Training
- Resources for Professionals
- For Employees
- Employee Alerts
- Employee Resources
- Doing Business
- Vendors & Suppliers
- Partners & Affiliates

